K 8 scripts

Descrizione Del Prodotto

Oxycodone Hydrochloride 15 mg Tablets USP (debossed with “K” on one side and “8” on the reverse) are an immediate-release oral opioid formulation engineered for rapid-onset analgesic efficacy. As a pure agonist with no intrinsic antagonist properties, oxycodone exerts its primary therapeutic effect by binding to stereospecific $\mu$-opioid receptors throughout the central nervous system (CNS), inhibiting ascending pain pathways and altering emotional response to pain.

Physical Specifications & Manufacturing Details

• Imprint: “K” debossed on one side; “8” debossed on the reverse

• Visual Characteristics: Light green, round, unscored or bisected convex tablet

• Strength / Active Moiety: 15 mg Oxycodone Hydrochloride USP

• Manufacturer / Labeler: KVK-Tech, Inc.

• National Drug Code (NDC): 10702-0008

Farmacocinetica clinica

• Absorption & Onset: Rapidly absorbed from the GI tract with measurable pain relief within 15–30 minutes and peak analgesic concentrations ($C_{\max}$) achieved within 1 to 2 hours.

• Metabolism: Primarily metabolized in the liver via CYP3A4 (to noroxycodone) and CYP2D6 (to oxymorphone).

• Elimination: Excreted predominantly through the renal system with a mean elimination half-life of 3.2 hours.

Boxed Warnings & Safety Compliance

• Addiction, Abuse, and Misuse: Schedule II controlled substance carrying high risks of opioid use disorder, overdose, and death. Assess patient risk factors prior to initiating therapy.

• Life-Threatening Respiratory Depression: Serious, life-threatening, or fatal respiratory depression may occur. Monitor closely, especially during treatment initiation or dose escalation.

• Accidental Ingestion: Accidental ingestion of even a single dose, especially by children, can result in fatal overdose. Secure storage in a locked location is mandatory.

• Concomitant Use with CNS Depressants: Co-administration with benzodiazepines, alcohol, or other CNS depressants may result in profound sedation, coma, or respiratory failure